quarta-feira, 7 de outubro de 2026
PesquisarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· February 6, 2026

Stocks to watch next week: BP, Barclays, AstraZeneca, Airbnb and Coinbase

View original at uk.finance.yahoo.com
Stocks to watch next week: BP, Barclays, AstraZeneca, Airbnb and Coinbase Earnings seasons is cooling down but investors will get updates from some heavyweights on both sides of the pond…
Opening lines of the source · short snapshot — read the full document at the original

O que extraímos desta fonte

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Hotels on Airbnb platform expected to improve conversion rates in supply-constrained urban markets

    80% confidence
  • Barclays remains the preferred play in the UK banking sector by some distance

    80% confidence
  • Potential launch of advertising presents a meaningful incremental EBITDA opportunity for Airbnb

    80% confidence
  • Barclays previously guided that shareholder returns would be skewed more towards buybacks rather than progressive dividend policy and reiterated ambitious aim of £10bn of returns between 2024 and 2026

    80% confidence
  • AstraZeneca guidance for 2025 pointing to high single digit revenue growth and low double digit growth in adjusted earnings per share on constant currency basis

    80% confidence
  • Airbnb is the world's largest travel brand without a loyalty programme or an advertising business, calling both something that we're absolutely looking at

    80% confidence
  • BP expected to book write down of $4bn to $5bn primarily related to transition business

    80% confidence
  • BP expected to report weak oil trading result for fourth quarter

    80% confidence

Data points we hold from this source

Barclays · pre tax profit2.08 billion_GBP
Barclays · total income7.17 billion_GBP
Barclays · car finance provision325 million_GBP
O que sabemos · a inteligência por trás desta página
Ao vivo do substrato
O que estamos a ver
Obesity and Immunology Readouts, Big Pharma M&A and AI-Designed Drugs Converge Into a Q4 2026 Catalyst Wave
Late-stage data and deal activity are clustering ahead of Q4 2026. Novo Nordisk's CagriSema won Best Abstract at EASD 2026 for its brain and body (fMRI/MRI) data, Lilly showed ADtouch results for EBGLYSS and agreed to buy Merida Biosciences for $2.9B, and Merck's tulisokibart hit its Phase 2b endpoints. A key regulatory catalyst follows: the FDA PDUFA date for the ivonescimab BLA on 2026-11-14. AI-designed rentosertib showing anti-aging effects adds a speculative AI-drug-discovery thread, while QAIAx's microcities trial and QIII pilot (planned 2027-01-01) are peripheral, forecast-only items.
A nossa leitura dos dados ›
Sinais que acompanhamos
Satellite-Terrestrial Network Integration Acceleration
Increased investment and launches in hybrid satellite-cellular networks across telecom industry; competitive responses from other carriers; regulatory activity around satellite spectrum; expansion of emergency/rural connectivity use cases
Padrões que observamos ›
Onde as fontes divergem
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Sinalizamos conflitos abertamente ›
Verificado recentemente
✓ Verificado com a fonte original
4,985
factos rastreados à sua fonte — e sinalizamos os que não se confirmam.
101 entidades acompanhadas4,985 factos verificados com a fonte5,351 documentos-fonte arquivados
Consulte estes dados → isubstrate.com